Cerenome (CNSY) Q3 2026 earnings summary

Executive summary

• First quarter of CNSide diagnostic revenue; Q3 revenue was $722K, net loss was $8.657M, and quarter-end cash, cash equivalents and restricted cash were $879K.

• Strategy spans CNSide diagnostics and investigational targeted radiotherapeutics; RESPECT-GBM Phase 2 enrollment ended in October at 32 patients, with topline data expected mid-2027.

Financial highlights

• Q3 revenue was $722K, all from Diagnostics, versus $1.397M in Q3 2025; 9M revenue was $2.161M versus $3.846M, including $1.439M in grant revenue.

• Q3 operating loss was $7.455M versus $4.482M; net loss was $8.657M versus $4.423M. 9M operating loss was $23.631M versus $9.556M; net loss was $24.609M versus $16.673M.

• Q3 diagnostic cost of revenue was $912K; 9M operating expenses were $25.792M, including $9.237M R&D and $15.643M SG&A.

• 9M operating cash use was $21.044M versus $14.518M; financing cash inflow was $14.330M versus $27.508M.

Outlook and guidance

• RESPECT-GBM Phase 2 ended in October after 32 patients; topline data is expected mid-2027 after further follow-up.

• RESPECT-LM repeat-dose Phase 1/2 dose escalation continues; the first 10 patients had no reported dose-limiting toxicities or adverse-event discontinuations. A DoD-funded pediatric brain cancer trial is enrolling at one U.S. site.

• CNSide CSF Cellular Biomarkers were expected to launch in Q4 2026; Molecular Profile tests launched in October and became orderable October 12.

• Medicare reimbursement was targeted for H1 2027; a separate coverage determination is being pursued from Novitas Solutions.